NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today a major strategic initiative to develop Guanilib, its guanylate cyclase C receptor (GCCR) agonist. Guanilib will be developed primarily for chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C).
